164 related articles for article (PubMed ID: 24045365)
1. Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin.
Lee DH; Lee CS; Kim DW; Ae JE; Lee TH
Anticancer Drugs; 2014 Jan; 25(1):44-52. PubMed ID: 24045365
[TBL] [Abstract][Full Text] [Related]
2. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
3. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
[TBL] [Abstract][Full Text] [Related]
4. Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.
Kim JY; Kim EH; Kim SU; Kwon TK; Choi KS
Carcinogenesis; 2010 Mar; 31(3):367-75. PubMed ID: 19939880
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.
Eramo A; Pallini R; Lotti F; Sette G; Patti M; Bartucci M; Ricci-Vitiani L; Signore M; Stassi G; Larocca LM; Crinò L; Peschle C; De Maria R
Cancer Res; 2005 Dec; 65(24):11469-77. PubMed ID: 16357155
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS
Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319
[TBL] [Abstract][Full Text] [Related]
7. Snake venom toxin from Vipera lebetina turanica sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins.
Park MH; Jo M; Won D; Song HS; Song MJ; Hong JT
Apoptosis; 2012 Dec; 17(12):1316-26. PubMed ID: 23007278
[TBL] [Abstract][Full Text] [Related]
8. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.
Son YG; Kim EH; Kim JY; Kim SU; Kwon TK; Yoon AR; Yun CO; Choi KS
Cancer Res; 2007 Sep; 67(17):8274-84. PubMed ID: 17804742
[TBL] [Abstract][Full Text] [Related]
9. 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis.
Siegelin MD; Habel A; Gaiser T
Neurobiol Dis; 2009 Feb; 33(2):243-9. PubMed ID: 19027068
[TBL] [Abstract][Full Text] [Related]
10. Phenethyl isothiocyanate sensitizes glioma cells to TRAIL-induced apoptosis.
Lee DH; Kim DW; Lee HC; Lee JH; Lee TH
Biochem Biophys Res Commun; 2014 Apr; 446(4):815-21. PubMed ID: 24491546
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D
FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587
[TBL] [Abstract][Full Text] [Related]
13. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation.
Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS
J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Bangert A; Cristofanon S; Eckhardt I; Abhari BA; Kolodziej S; Häcker S; Vellanki SH; Lausen J; Debatin KM; Fulda S
Oncogene; 2012 Nov; 31(44):4677-88. PubMed ID: 22266862
[TBL] [Abstract][Full Text] [Related]
15. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; Ahnert P; Meixensberger J; Walczak H
Clin Cancer Res; 2007 Jun; 13(11):3403-12. PubMed ID: 17545549
[TBL] [Abstract][Full Text] [Related]
17. Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.
Tse AK; Cao HH; Cheng CY; Kwan HY; Yu H; Fong WF; Yu ZL
J Invest Dermatol; 2014 May; 134(5):1397-1407. PubMed ID: 24213373
[TBL] [Abstract][Full Text] [Related]
18. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
19. Tunicamycin sensitizes human prostate cells to TRAIL-induced apoptosis by upregulation of TRAIL receptors and downregulation of cIAP2.
Jung YH; Lim EJ; Heo J; Kwon TK; Kim YH
Int J Oncol; 2012 Jun; 40(6):1941-8. PubMed ID: 22426894
[TBL] [Abstract][Full Text] [Related]
20. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
Premkumar DR; Jane EP; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
